Claire Roddie, PhD, FRCPath, MBChB, MRCP, discusses outcomes with obe-cel by disease burden at screening/lymphodepletion in B-cell acute lymphoblastic leukemia.
Claire Roddie, PhD, FRCPath, MBChB, MRCP
Advertisement
Claire Roddie, PhD, FRCPath, MBChB, MRCP, is an associate professor in hematology at the University College London, an honorary hemato-oncology/cell therapies consultant at University College London Hospitals, and clinical science director of CAR-T and Vector at the Centre for Cell, Gene and Tissue Therapeutics/Royal Free Hospital.
Articles by Claire Roddie, PhD, FRCPath, MBChB, MRCP
Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.
Advertisement
Latest Updated Articles
Dr Roddie on Obe-cel in R/R B-ALLJune 3rd 2023
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5